Biocon Slips 1% on Biologics Buyout, Fundraise Nod
Shares of Biocon Ltd fell 1% after hitting a day’s high of Rs 395.60 on 8th December, following the company’s announcement that it will convert its subsidiary, Biocon Biologics, into a 100% wholly owned unit. The company said it will issue shares to Biocon Biologics’ shareholders at Rs 405.6 per... The post Biocon Slips 1% on Biologics Buyout, Fundraise Nod appeared first on Equitypandit.
Shares of Biocon Ltd fell 1% after hitting a day’s high of Rs 395.60 on 8th December, following the company’s announcement that it will convert its subsidiary, Biocon Biologics, into a 100% wholly owned unit.
The company said it will issue shares to Biocon Biologics’ shareholders at Rs 405.6 per share, a 3.3% premium to Biocon’s closing price last Friday. This will lead to an equity dilution of 17.1 crore shares, valued at Rs 6,591 crore. The company will also need an additional $400 million (Rs 3,598 crore) to pay Mylan, which holds a 6.09% stake.
As part of the announcement, the board has also approved raising Rs 4,500 crore through a Qualified Institutional Placement. The deal values Biocon Biologics at $5.5 billion.
After the deal, promoter holding in Biocon will fall below 50%.
At 11:43 AM, shares of Biocon Ltd were trading 1.10% lower at Rs 388.35 on NSE.
The post Biocon Slips 1% on Biologics Buyout, Fundraise Nod appeared first on Equitypandit.
What's Your Reaction?
